This study offers novel insights into the impact of CD44/HAS1/MMP9 on ccRCC tumorigenesis and invasion, with potential implications for early metastasis prediction and the development of more effective treatment strategies. This evidence concerns the gene CD44 and nonpapillary renal cell carcinoma.